140 related articles for article (PubMed ID: 29441502)
21. Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations.
Jenei K; Meyers DE
BMJ Open; 2023 Oct; 13(10):e066378. PubMed ID: 37844982
[TBL] [Abstract][Full Text] [Related]
22. Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study.
Lexchin J
PLoS One; 2019; 14(2):e0212399. PubMed ID: 30768629
[TBL] [Abstract][Full Text] [Related]
23. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
Rocchi A; Menon D; Verma S; Miller E
Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
[TBL] [Abstract][Full Text] [Related]
24. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.
Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C
Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899
[TBL] [Abstract][Full Text] [Related]
25. Guidelines for health technologies: specific guidance for oncology products in Canada.
Mittmann N; Evans WK; Rocchi A; Longo CJ; Au HJ; Husereau D; Leighl NB; Isogai PK; Krahn MD; Peacock S; Marshall D; Coyle D; Taylor SC; Jacobs P; Oh PI
Value Health; 2012 May; 15(3):580-5. PubMed ID: 22583470
[TBL] [Abstract][Full Text] [Related]
26. Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada.
Nagase FNI; Stafinski T; Sun J; Jhangri G; Menon D
Orphanet J Rare Dis; 2019 Jun; 14(1):127. PubMed ID: 31174574
[TBL] [Abstract][Full Text] [Related]
27. Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans.
Salek S; Lussier Hoskyn S; Johns JR; Allen N; Sehgal C
Front Pharmacol; 2019; 10():196. PubMed ID: 30983993
[TBL] [Abstract][Full Text] [Related]
28. Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug Review.
Niraula S
Cancer; 2019 Sep; 125(18):3100-3103. PubMed ID: 31154671
[TBL] [Abstract][Full Text] [Related]
29. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
Allen D; Gillen E; Rixson L
JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
[TBL] [Abstract][Full Text] [Related]
30. Patients' perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH Common Drug Review.
Berglas S; Jutai L; MacKean G; Weeks L
Res Involv Engagem; 2016; 2():21. PubMed ID: 29062521
[TBL] [Abstract][Full Text] [Related]
31. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
[TBL] [Abstract][Full Text] [Related]
32. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
33. The impact of cancer drug wastage on economic evaluations.
Truong J; Cheung MC; Mai H; Letargo J; Chambers A; Sabharwal M; Trudeau ME; Chan KKW
Cancer; 2017 Sep; 123(18):3583-3590. PubMed ID: 28640362
[TBL] [Abstract][Full Text] [Related]
34. Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea.
Bae G; Bae EY; Bae S
Health Policy; 2015 May; 119(5):577-87. PubMed ID: 25666339
[TBL] [Abstract][Full Text] [Related]
35. Disparity in public funding of systemic therapy for metastatic renal cell carcinoma in Canada.
Jackson EB; Hotte SJ
Can Urol Assoc J; 2022 Nov; 16(11):E516-E522. PubMed ID: 35704937
[TBL] [Abstract][Full Text] [Related]
36. Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada.
Jenei K; Peacock S; Burgess M; Mitton C
Curr Oncol; 2021 Jul; 28(4):2708-2719. PubMed ID: 34287280
[TBL] [Abstract][Full Text] [Related]
37. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
38. A research roadmap for complementary and alternative medicine - what we need to know by 2020.
Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B
Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
